Jeff B Smith joins EBT Board, bringing vast consumer healthcare experience.
Boston, Massachusetts and Toronto, Ontario – January 18, 2021 – EBT Medical, Inc. (“EBT”) a venture-backed clinical-stage company reimagining the treatment for pelvic health disorders, is pleased to announce the appointment of Jeff B. Smith to the Board of Directors.
“I’m thrilled to join EBT as it rounds out its leadership, completes its first product, and races toward commercialization,” said Mr. Smith. “The team has made tremendous progress to date, and given the compelling clinical data amassed, I see enormous potential to address multiple large markets, starting with overactive bladder. Especially at a time when patients are less inclined take another pill or undergo surgery, EBT offers the promise of treating patients in the comfort & safety of their own homes.”
Jeff served in various key leadership roles at Johnson & Johnson, the world’s largest and most diversified healthcare company. Most recently, he served as Company Group Chairman, North America and oversaw several divisions and brands including Tylenol®, Zyrtec®, Band-Aid Brand®, Neutrogena®, and others. During his time at J&J, he developed a strong track record of building and marketing global brands, driving insight-driven innovations, leading strategic business turnarounds, and delivering profitable growth.
Retiring from J&J, Jeff co-founded and is Managing Partner of Ignite Venture Studio, which develops brands to disrupt the ‘startup-quo’ by building and accelerating their performance to achieve success in collaboration with strategic partners. Recent launches include Paragon Vitamins, a subscription service personalized through metabolic testing, and Fluent Health, an integrated direct-to-patient solution for influenza and the common cold.
“I’m passionate about building brands that offer high-quality solutions to help people live their best lives every day. EBT is developing products that address major health issues in revolutionary ways, bringing neuromodulation into the mainstream,” said Smith.
“We’re delighted to welcome Jeff to our Board,” said Keith Carlton, CEO of EBT Medical. “Jeff brings deep operational experience, an expansive network, and a very strong consumer healthcare background which perfectly complements our Executive Team and Board. We are thrilled to have his guidance and insights as we drive EBT forward.”
About EBT Medical
EBT Medical was founded in 2014 based on scientific discoveries made at the University of Toronto with a mission to develop novel neuromodulation technologies that restore control, dignity and independence to those silently suffering from pelvic floor disorders. EBT’s first product is a clinical-grade, noninvasive neurostimulator and associated ecosystem for overactive bladder (OAB). EBT has a significant patent estate around multiple neuromodulation technologies including issued patents on the Saphenous nerve for all pelvic health indications. EBT’s management team and world-class advisory board have decades of relevant experience in pelvic health, neuromodulation, and consumer health. Learn more about EBT Medical at www.ebtmedical.com
About Overactive Bladder and Neuromodulation
Overactive bladder is a disabling syndrome affecting nearly 550M worldwide1. It is characterized by frequent, sudden, uncontrollable urges to void, often followed by incontinence episodes that are embarrassing and significantly impede activities of daily living. The major symptom of OAB, Urge Urinary Incontinence (UUI), is thought to be caused by over-signaling to & from the bladder and the pontine micturition center located in the brain stem. Over 50%2 of those with OAB remain undiagnosed and silently suffer, with marked increases in depression, anxiety, sleeplessness due to nocturia (waking to void), and social isolation. The economic impact of OAB in the United States was estimated at $76B including direct costs and indirect costs such as increased urinary tract infections, falls from running to the bathroom, and absenteeism3. Neuromodulation has been an established therapy for UUI since it was first approved in 1997.
Contact
Keith R Carlton
Chief Executive Officer
[email protected]
1 546M affected individuals in 2018. Filipetto et al.: The patient perspective on overactive bladder: a mixed-methods needs assessment. BMC Family Practice 2014 15:96.
2 Ibid.
3$76B in 2015. J Manag Care Pharm. 2014 Feb;20(2):130-40. “Economic burden of urgency urinary incontinence in the United States: a systematic review.”
